149 related articles for article (PubMed ID: 35508379)
1. Visibility of liquid embolic agents in fluoroscopy: a systematic in vitro study.
Schmitt N; Wucherpfennig L; Hohenstatt S; Weyland CS; Sommer CM; Bendszus M; Möhlenbruch MA; Vollherbst DF
J Neurointerv Surg; 2023 Jun; 15(6):594-599. PubMed ID: 35508379
[TBL] [Abstract][Full Text] [Related]
2. Material-Specific Roadmap Modes Can Improve the Visibility of Liquid Embolic Agents for Endovascular Embolization: A Systematic In Vitro Study.
Schmitt N; Wucherpfennig L; Hohenstatt S; Karimian-Jazi K; Breckwoldt MO; Kauczor HU; Bendszus M; Möhlenbruch MA; Vollherbst DF
AJNR Am J Neuroradiol; 2022 Dec; 43(12):1749-1755. PubMed ID: 36357152
[TBL] [Abstract][Full Text] [Related]
3. Imaging Artifacts of Nonadhesive Liquid Embolic Agents in Conventional and Cone-beam CT in a Novel in Vitro AVM Model.
Schmitt N; Floca RO; Paech D; El Shafie RA; Neuberger U; Bendszus M; Möhlenbruch MA; Vollherbst DF
Clin Neuroradiol; 2021 Dec; 31(4):1141-1148. PubMed ID: 33852036
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a novel liquid embolic agent (precipitating hydrophobic injectable liquid (PHIL)) in an animal endovascular embolization model.
Vollherbst DF; Otto R; von Deimling A; Pfaff J; Ulfert C; Kauczor HU; Bendszus M; Sommer CM; Möhlenbruch MA
J Neurointerv Surg; 2018 Mar; 10(3):268-274. PubMed ID: 28689184
[TBL] [Abstract][Full Text] [Related]
5. Imaging Artifacts of Liquid Embolic Agents on Conventional CT in an Experimental in Vitro Model.
Schmitt N; Floca RO; Paech D; El Shafie RA; Seker F; Bendszus M; Möhlenbruch MA; Vollherbst DF
AJNR Am J Neuroradiol; 2021 Jan; 42(1):126-131. PubMed ID: 33214178
[TBL] [Abstract][Full Text] [Related]
6. Glue, Onyx, Squid or PHIL? Liquid Embolic Agents for the Embolization of Cerebral Arteriovenous Malformations and Dural Arteriovenous Fistulas.
Vollherbst DF; Chapot R; Bendszus M; Möhlenbruch MA
Clin Neuroradiol; 2022 Mar; 32(1):25-38. PubMed ID: 34324005
[TBL] [Abstract][Full Text] [Related]
7. Liquid Embolic Agents for Endovascular Embolization: Evaluation of an Established (Onyx) and a Novel (PHIL) Embolic Agent in an In Vitro AVM Model.
Vollherbst DF; Sommer CM; Ulfert C; Pfaff J; Bendszus M; Möhlenbruch MA
AJNR Am J Neuroradiol; 2017 Jul; 38(7):1377-1382. PubMed ID: 28522669
[TBL] [Abstract][Full Text] [Related]
8. Comparison of N-butyl cyanoacrylate and onyx for the embolization of intracranial arteriovenous malformations: analysis of fluoroscopy and procedure times.
Velat GJ; Reavey-Cantwell JF; Sistrom C; Smullen D; Fautheree GL; Whiting J; Lewis SB; Mericle RA; Firment CS; Hoh BL
Neurosurgery; 2008 Jul; 63(1 Suppl 1):ONS73-8; discussion ONS78-80. PubMed ID: 18728607
[TBL] [Abstract][Full Text] [Related]
9. Initial experience with precipitating hydrophobic injectable liquid in cerebral arteriovenous malformations.
Sirakov SS; Sirakov A; Minkin K; Hristov H; Ninov K; Penkov M; Karakostov V; Orlov K; Gorbatykh A; Kislitsin D; Raychev R
Interv Neuroradiol; 2019 Feb; 25(1):58-65. PubMed ID: 30223686
[TBL] [Abstract][Full Text] [Related]
10. Neurological morbidity and mortality associated with the endovascular treatment of cerebral arteriovenous malformations before and during the Onyx era.
Crowley RW; Ducruet AF; Kalani MY; Kim LJ; Albuquerque FC; McDougall CG
J Neurosurg; 2015 Jun; 122(6):1492-7. PubMed ID: 25816081
[TBL] [Abstract][Full Text] [Related]
11. Precipitating hydrophobic injectable liquid embolization of intracranial vascular shunts: initial experience and technical note.
Varadharajan S; Ramalingaiah AH; Saini J; Gupta AK; Devi BI; Acharya UV
J Neurosurg; 2018 Nov; 129(5):1217-1222. PubMed ID: 29192863
[TBL] [Abstract][Full Text] [Related]
12. Preliminary experience with the liquid embolic material agent PHIL (Precipitating Hydrophobic Injectable Liquid) in treating cranial and spinal dural arteriovenous fistulas: technical note.
Leyon JJ; Chavda S; Thomas A; Lamin S
J Neurointerv Surg; 2016 Jun; 8(6):596-602. PubMed ID: 25994938
[TBL] [Abstract][Full Text] [Related]
13. Novel use of precipitating hydrophobic injectable liquid (PHIL) in pre-operative angioembolisation of a large posterior auricular arteriovenous malformation.
Chu C; Tan THL; Ng KS; Tan CS; Lee TS; Yuen HW; Lee W; Huang XY
Am J Otolaryngol; 2023; 44(2):103786. PubMed ID: 36680841
[TBL] [Abstract][Full Text] [Related]
14. Histopathological changes in brain arteriovenous malformations after embolization using Onyx or N-butyl cyanoacrylate. Laboratory investigation.
Natarajan SK; Born D; Ghodke B; Britz GW; Sekhar LN
J Neurosurg; 2009 Jul; 111(1):105-13. PubMed ID: 19326974
[TBL] [Abstract][Full Text] [Related]
15. Investigation of a New Version of the Liquid Embolic Agent PHIL with Extra-Low-Viscosity in an Endovascular Embolization Model.
Vollherbst DF; Otto R; Hantz M; Ulfert C; Kauczor HU; Bendszus M; Sommer CM; Möhlenbruch MA
AJNR Am J Neuroradiol; 2018 Sep; 39(9):1696-1702. PubMed ID: 30093480
[TBL] [Abstract][Full Text] [Related]
16. Embolization of Intracranial Dural Arteriovenous Fistulas Using PHIL Liquid Embolic Agent in 26 Patients: A Multicenter Study.
Lamin S; Chew HS; Chavda S; Thomas A; Piano M; Quilici L; Pero G; Holtmannspolter M; Cronqvist ME; Casasco A; Guimaraens L; Paul L; Gil Garcia A; Aleu A; Chapot R
AJNR Am J Neuroradiol; 2017 Jan; 38(1):127-131. PubMed ID: 27932510
[TBL] [Abstract][Full Text] [Related]
17. A prospective, multicenter, randomized trial of the Onyx liquid embolic system and N-butyl cyanoacrylate embolization of cerebral arteriovenous malformations. Clinical article.
Loh Y; Duckwiler GR;
J Neurosurg; 2010 Oct; 113(4):733-41. PubMed ID: 20433277
[TBL] [Abstract][Full Text] [Related]
18. Embolization of peripheral arteriovenous malformations and fistulas with precipitating hydrophobic injectable liquid (PHIL
Giurazza F; Corvino F; Silvestre M; Cangiano G; De Magistris G; Cavaglià E; Amodio F; Niola R
Radiol Med; 2021 Mar; 126(3):474-483. PubMed ID: 32889705
[TBL] [Abstract][Full Text] [Related]
19. Combined therapy of cerebral arteriovenous malformations: histological differences between a non-adhesive liquid embolic agent and n-butyl 2-cyanoacrylate (NBCA).
Duffner F; Ritz R; Bornemann A; Freudenstein D; Wiendl H; Siekmann R
Clin Neuropathol; 2002; 21(1):13-7. PubMed ID: 11846039
[TBL] [Abstract][Full Text] [Related]
20. Neurological outcomes and cure rates of embolization of brain arteriovenous malformations with n-butyl cyanoacrylate or Onyx: a meta-analysis.
Elsenousi A; Aletich VA; Alaraj A
J Neurointerv Surg; 2016 Mar; 8(3):265-72. PubMed ID: 25540177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
